... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
Medicine Products:... hazardous multiple births, women undergoing IVF (...le embryo without reducing their chances of having... one embryo at a time to the womb can marginally r...he study, led by Yacoub Khalaf, of Guys Hospital, ...
...or cells migrate to the lymphatic system in the ea... by a swiss-based research team. This new underst...anti-metastasis therapies. Scientists know that t...tem, but they dont understand the details of how t...
...y against South Korea's hard-drinking culture whic...conomic losses, officials said . The campaign focu...to enhance public awareness of the dangers of exce...th and Welfare said. "South Koreans consider offe...
...n surgeons got a shock when the patient they were ... Describing the case in the Lancet, lead doctor D...er, wrote how his team was startled to discover gr...s of a man prepped for surgery. The 42-year-old m...
Other Medicine News:Health News:Single Embryo IVF Increase Chances of Having Child Sans Risky Multiple Births 2Health News:Developing Antimetastasis Therapy- An Early Stage of Tumor Control. 2(Date:12/3/2008)...n, a contract development and,manufacturing organ...ined a,strategic financial partner to help it exp...d for Isogen,s services. , Isogen has previ... capital,investment and the opening of its first ...e previously unmet process, facility and capacity ...
(Date:12/3/2008)...stCall/ -- Bionovo, Inc.,(Nasdaq: BNVI ) today ...,manufacturing and control process descriptions (C... move forward with the development of Menerba,(fo... "We have concluded three CMC discussions wi...s recommendations for further development of Mener...
(Date:12/2/2008)... Researchers using functional,MRI (fMRI) have det...n,responsible for suppressing memory is dysfuncti...ychiatric disorders. Results of the study will be ...ological Society of North America,(RSNA). , ...ress-related disorders,traumatic memories are a ...
(Date:12/2/2008)...Call/ -- Biopure Corporation,(Nasdaq: BPUR ) an... Center,(NMRC) has submitted to the Food and Drug...ew drug (IND) application to conduct a clinical tr...R) [hemoglobin glutamer - 250 (bovine)],for the p...ts. The study is,entitled "Operation Restore Effe...
Breaking Medicine Technology:Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand 2Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand 3Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings 2Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings 3Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings 4Stress-Related Disorders Affect Brain's Processing of Memory 2Stress-Related Disorders Affect Brain's Processing of Memory 3U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 2U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 3BioReliance Corporation Launches iNet 28TM 29 for Online Results Tracking of Biological Safety Tests 641 1BioReliance Corporation Launches iNet 28TM 29 for Online Results Tracking of Biological Safety Tests 641 2ViPS Awarded Enterprise Systems Development 28ESD 29 Contract By CMS 636 1ViPS Awarded Enterprise Systems Development 28ESD 29 Contract By CMS 636 2ViPS Awarded Enterprise Systems Development 28ESD 29 Contract By CMS 636 3Leeza Gibbons Leads New Coaching Program to Boost the Nations Heart Health 1449 1Leeza Gibbons Leads New Coaching Program to Boost the Nations Heart Health 1449 2Leeza Gibbons Leads New Coaching Program to Boost the Nations Heart Health 1449 3Leeza Gibbons Leads New Coaching Program to Boost the Nations Heart Health 1449 4Wellcorps International Unveils New Nutritional Supplements 1444 1Wellcorps International Unveils New Nutritional Supplements 1444 2...ernational Symposium,of Thrombosis and Haemostasis...Baxter,Healthcare Corporation today announced the ...of Data from ADVATE(R) Prospective Trials),study p...t,relationship between the duration of time spent ...nal unit per deciliter (1 IU/dL,one percent of no...
...-- Phase 3 results,from the RE-NOVATE(TM) trial de...ly, administered for an average of 33 days, was,no... average of 33,days, in preventing venous thromboe...hip replacement surgery. In this trial, the,rate o...ate was,similar to enoxaparin. The incidence of li...
Other Medicine Technology:Clinical Data Suggest Decreased Bleeding Risk in People With Severe,Hemophilia A While Maintaining Factor VIII Levels Above One Percent 2Clinical Data Suggest Decreased Bleeding Risk in People With Severe,Hemophilia A While Maintaining Factor VIII Levels Above One Percent 3Clinical Data Suggest Decreased Bleeding Risk in People With Severe,Hemophilia A While Maintaining Factor VIII Levels Above One Percent 4Clinical Data Suggest Decreased Bleeding Risk in People With Severe,Hemophilia A While Maintaining Factor VIII Levels Above One Percent 5Phase 3 Results for Dabigatran Etexilate, an Investigational Oral,Anticoagulant, Presented Today at the XXIst Congress of the,International Society on Thrombosis and Haemostasis 2Phase 3 Results for Dabigatran Etexilate, an Investigational Oral,Anticoagulant, Presented Today at the XXIst Congress of the,International Society on Thrombosis and Haemostasis 3Phase 3 Results for Dabigatran Etexilate, an Investigational Oral,Anticoagulant, Presented Today at the XXIst Congress of the,International Society on Thrombosis and Haemostasis 4Phase 3 Results for Dabigatran Etexilate, an Investigational Oral,Anticoagulant, Presented Today at the XXIst Congress of the,International Society on Thrombosis and Haemostasis 5